GGrantIndex
Sort

78,016 grants matching breast cancer

VDX-111: A novel targeted therapeutic for triple-negative breast cancer

$995,137
Cherie Lambert · Vona Oncology, Llc · R44 · FY2024 · CA

Building a Sustainable Indian Tribal Infrastructure for Translational Research

$995,133
Carolyn June Strickland · University Of Washington · RC4 · FY2010 · NR

Development of VNLG-152R as novel therapeutic for triple negative breast cancer

$995,100
Vidya P Ramamurthy · Isoprene Pharmaceuticals, Inc. · R44 · FY2021 · CA

Development of VNLG-152R as novel therapeutic for triple negative breast cancer

$995,100
Vidya P Ramamurthy · Isoprene Pharmaceuticals, Inc. · R44 · FY2022 · CA

Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry

$994,901
Christine B. Ambrosone · Roswell Park Cancer Institute Corp · R01 · FY2020 · CA

Rapid Identification of Pathogenic Bacteria and Sepsis Diagnosis

$994,871
Ray Anthony Martino · Isense, Llc · R44 · FY2013 · AI

Leadership, Planning and Evaluation

$994,847
Caryn Lerman · University Of Southern California · P30 · FY2023 · CA

BAY AREA BREAST CANCER TRANSLATIONAL RESEARCH PROGRAM

$994,561
University Of California San Francisco · P50 · FY2002 · CA

3D Bioprinted lung cancer models for drug screening

$994,549
Marc Ferrer · National Center For Advancing Translational Sciences · ZIA · FY2024 · TR

Building Sustainable Community-based Research Infrastructure to Better Science (C

$994,445
Marion Helen Eloise Kavanaugh-Lynch · University Of California Sys Office/Pres · RC4 · FY2010 · ES

Estrogen Metabolites, Related Genes and Breast Cancer

$994,129
New York University School Of Medicine · R01 · FY2003 · CA

Enabling clinical tissue microstructure imaging as a diagnostic tool in wide-bore 3T MRI

$993,663
Thomas K Foo · Ge Medical Systems Information Technologies, Inc · U01 · FY2024 · EB

Cancer Deep Phenotype Extraction from Electronic Medical Records

$993,015
Guergana K. Savova · Boston Children'S Hospital · U24 · FY2018 · CA

Tumor Immune Contexture and Breast Cancer Disparities: A Multi-Disciplinary Study in Women of African and European Ancestry

$993,003
Christine B. Ambrosone · Roswell Park Cancer Institute Corp · R01 · FY2022 · CA

Developing novel LOX inhibitors to target chemotherapy resistant TNBC

$992,932
Ozgur Sahin · Loxigen, Inc. · R42 · FY2024 · CA

Immunomodulatory biomaterial to enhancing T-cell responses to triple negative breast cancer

$992,724
Dashtimoghadam Erfan · Symphony Biosciences, Inc. · R44 · FY2024 · CA

Molecular, Cellular, and Tissue Characterization Unit

$992,570
William E Gillanders · Washington University · U2C · FY2020 · CA

Bay Area Cancer Target Discovery and Development

$992,465
Michael T McManus · University Of California, San Francisco · U01 · FY2025 · CA

Randomized Prospective Trial of Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer

$992,343
Venkataramanan Krishnaswamy · Cairnsurgical, Inc. · R44 · FY2021 · CA

Human natural killer cells: Advancing biology and clinical applications

$992,214
Michael A Caligiuri · Beckman Research Institute/City Of Hope · R35 · FY2018 · CA

Robust Predictor of Breast Cancer Risk

$991,797
Harry Ostrer · Morgan And Mendel Genomics, Inc. · R42 · FY2020 · CA

Characterization of Cancer Stem Cells

$991,766
William Farrar · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA

Elucidating and Targeting tumor dependencies and drug resistance determinants at the single cell level

$991,182
Andrea Califano · Columbia University Health Sciences · U01 · FY2022 · CA

Commercializing Praedicare Dx TM platform for guiding cancer treatments

$991,179
Michael H Cardone · Eutropics Pharmaceuticals, Inc. · R44 · FY2018 · CA

CCTN - CONTRACEPTIVE EFFICACY AND SAFETY OF DAILY ORAL ULIPRISTAL ACETATE

$991,117
Erin Allen · Columbia University Health Sciences · N02 · FY2013 · HD